BioCentury | May 23, 2016
Company News

Anacor, Pfizer deal

...tumor necrosis factor (TNF) alpha , IL-12 and IL-23. Pfizer also will gain Anacor’s Kerydin tavaborole...
BioCentury | May 17, 2016
Top Story

Pfizer acquiring Anacor for $5.2B

...NASDAQ:AMGN) (see BioCentury Extra, Jan. 19) . Pfizer also will gain Anacor's onychomycosis drug Kerydin tavaborole...
...in the U.S. In 2015, Anacor recorded $60.5 million in gross profit sharing revenue from Kerydin...
BioCentury | Apr 25, 2016
Politics, Policy & Law

SCOTUS to the rescue?

...apixaban from Bristol-Myers / Pfizer [1] Treximet naproxen / sumatriptan from Pernix [1] (A) Kerydin tavaborole...
BioCentury | Sep 14, 2015
Politics, Policy & Law

IPR battles

...etanercept 8,163,522 4/24/29 3 11/22/28 8/22/15 $530.8M (0%) -$1.5B (1%) Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) Kerydin tavaborole...
BioCentury | Sep 7, 2015
Company News

Anacor, Hayman Capital Management infectious news

...PTAB) of the U.S. Patent and Trademark Office challenging patents covering Anacor’s onychomycosis drug Kerydin tavaborole...
...and two petitions against U.S. Patent No. 7,767,657. The ‘657 patent claims topical formulations of Kerydin...
BioCentury | Aug 22, 2015
Company News

IPR petitions target Oracea, Kerydin

...Rosacea drug Oracea doxycycline from Galderma S.A. (Lausanne, Switzerland) and onychomycosis drug Kerydin tavaborole from Anacor...
...and two petitions against U.S. Patent No. 7,767,657. The '657 patent claims topical formulations of Kerydin...
...treat onychomycosis and related diseases. The '621 patent claims methods of treating fungal infections with Kerydin...
BioCentury | Aug 3, 2015
Company News

Anacor, Novartis deal

...commercialize onychomycosis drug Kerydin tavaborole. Under the amendment, Sandoz will increase its commercial investment in Kerydin...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...approves G-Lasta pegfilgrastim to treat chemotherapy-induced febrile neutropenia Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) FDA approves Kerydin tavaborole...
BioCentury | Sep 29, 2014
Company News

Anacor sales and marketing update

...said the Sandoz Inc. generics unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) launched Kerydin tavaborole...
...Sandoz has exclusive, U.S. commercialization rights under a July deal. Sandoz said it would distribute Kerydin...
BioCentury | Aug 18, 2014
Company News

Anacor, Novartis deal

...Anacor granted Novartis’ Sandoz Inc. generics unit exclusive rights in the U.S. to commercialize Kerydin tavaborole...
...in 2016 totaling $45 million. Anacor also has the option to repurchase all rights to Kerydin...
...from the launch of the drug or Dec. 31, 2017. Anacor will supply Sandoz with Kerydin...
Items per page:
1 - 10 of 65